

# Princeton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.90	4	NC*	Male	1.47	1	NC*
Female	0.59	1	NC*	Female	1.03	2	NC*
Total	2.49	5	200	Total	2.50	3	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.70	0	NC*	Male	0.41	0	NC*
Female	0.48	1	NC*	Female	0.30	0	NC*
Total	1.18	1	NC*	Total	0.71	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.10	0	NC*	Male	1.72	2	NC*
Female	12.50	11	88	Female	1.28	0	NC*
Total	12.59	11	87	Total	2.99	2	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.74	2	NC*	Male	1.48	0	NC*
				Female	0.58	1	NC*
				Total	2.06	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	4.85	5	103	Female	1.46	0	NC*
Female	3.68	2	NC*				
Total	8.52	7	82				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.80	0	NC*	Male	0.86	0	NC*
Female	0.18	0	NC*	Female	0.69	1	NC*
Total	0.98	0	NC*	Total	1.55	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.33	0	NC*	Male	13.49	9	67
Female	0.24	0	NC*				
Total	0.57	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.33	0	NC*	Male	0.83	1	NC*
Female	0.69	0	NC*	Female	0.39	0	NC*
Total	2.02	0	NC*	Total	1.23	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.79	0	NC*	Male	0.47	0	NC*
Female	0.17	0	NC*				
Total	0.96	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.99	2	NC*	Male	0.31	0	NC*
Female	0.68	0	NC*	Female	0.77	0	NC*
Total	1.67	2	NC*	Total	1.08	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.52	0	NC*	Female	2.44	2	NC*
Female	0.16	0	NC*				
Total	0.67	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	6.63	4	NC*	Male	42.69	30	70
Female	4.59	0	NC*	Female	35.95	23	64 #~
Total	11.22	4	NC*	Total	78.64	53	67 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Provincetown

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.57	4	NC*	Male	2.12	1	NC*
Female	1.32	2	NC*	Female	1.50	1	NC*
Total	4.88	6	123	Total	3.62	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.85	0	NC*	Male	0.67	0	NC*
Female	0.66	0	NC*	Female	0.57	1	NC*
Total	1.51	0	NC*	Total	1.24	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.16	0	NC*	Male	2.56	5	195
Female	18.82	17	90	Female	2.30	1	NC*
Total	18.98	17	90	Total	4.87	6	123
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.93	1	NC*	Male	2.01	1	NC*
				Female	0.96	0	NC*
				Total	2.98	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	8.76	8	91	Female	2.13	2	NC*
Female	8.26	10	121				
Total	17.03	18	106				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.22	3	NC*	Male	1.46	0	NC*
Female	0.40	0	NC*	Female	1.51	1	NC*
Total	1.62	3	NC*	Total	2.97	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.36	2	NC*	Male	21.49	20	93
Female	0.28	0	NC*				
Total	0.64	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.93	3	NC*	Male	1.48	3	NC*
Female	1.16	0	NC*	Female	0.90	2	NC*
Total	3.09	3	NC*	Total	2.38	5	210
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.12	1	NC*	Male	0.48	1	NC*
Female	0.26	1	NC*				
Total	1.38	2	NC*				

<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.47	4	NC*	Male	0.36	0	NC*
Female	1.12	1	NC*	Female	0.89	1	NC*
Total	2.59	5	193	Total	1.25	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.75	0	NC*	Female	3.67	4	NC*
Female	0.32	0	NC*				
Total	1.07	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	10.96	11	100	Male	68.29	91	133 #+
Female	8.11	14	173	Female	60.70	64	105
Total	19.07	25	131	Total	128.99	155	120 #+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Quincy

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	52.53	69	131 #+	Male	35.20	38	108
Female	25.53	35	137	Female	32.15	41	128
Total	78.07	104	133 ~+	Total	67.35	79	117
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	15.70	22	140	Male	10.10	8	79
Female	14.84	19	128	Female	11.03	11	100
Total	30.54	41	134	Total	21.13	19	90
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	2.44	3	NC*	Male	42.79	59	138 #+
Female	374.25	379	101	Female	47.05	38	81
Total	376.69	382	101	Total	89.84	97	108
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	21.75	29	133	Male	31.77	38	120
				Female	18.99	12	63
				Total	50.76	50	98
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	130.27	162	124 ~+	Female	43.78	41	94
Female	161.03	181	112				
Total	291.30	343	118 ~+				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	18.30	24	131	Male	21.78	26	119
Female	7.83	8	102	Female	29.34	30	102
Total	26.13	32	122	Total	51.11	56	110

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	8.55	6	70
Female	7.65	7	92
Total	16.19	13	80

**Kidney and Renal Pelvis**

Male	30.31	27	89
Female	23.11	19	82
Total	53.42	46	86

**Larynx**

Male	17.05	24	141
Female	5.08	9	177
Total	22.13	33	149 #+

**Leukemia**

Male	24.69	31	126
Female	23.35	21	90
Total	48.04	52	108

**Liver and Intrahepatic Bile Ducts**

Male	11.75	23	196 ~+
Female	6.30	5	79
Total	18.05	28	155 #+

**Lung and Bronchus**

Male	163.73	195	119 #+
Female	158.79	207	130 ^+
Total	322.52	402	125 ^+

**Prostate**

Male	317.00	347	109
------	--------	-----	-----

**Stomach**

Male	22.03	28	127
Female	17.67	14	79
Total	39.70	42	106

**Testis**

Male	13.94	16	115
------	-------	----	-----

**Thyroid**

Male	7.23	8	111
Female	22.28	17	76
Total	29.51	25	85

**Uteri, Corpus and Uterus, NOS**

Female	70.93	83	117
--------	-------	----	-----

**All Sites / Types**

Male	1049.47	1243	118 ^+
Female	1214.88	1308	108 ~+
Total	2264.35	2551	113 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Randolph**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	20.68	16	77	Male	13.95	11	79
Female	8.45	15	177	Female	11.28	14	124
Total	29.13	31	106	Total	25.23	25	99
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	6.25	2	NC*	Male	4.07	4	NC*
Female	5.29	6	113	Female	3.82	3	NC*
Total	11.54	8	69	Total	7.88	7	89
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.98	1	NC*	Male	16.80	25	149
Female	135.86	110	81 #-	Female	16.11	13	81
Total	136.85	111	81 #-	Total	32.90	38	115

**Cervix Uteri**

Female	7.65	2	NC*
--------	------	---	-----

**Colon / Rectum**

Male	51.59	70	136 #+
Female	52.88	49	93
Total	104.47	119	114

**Esophagus**

Male	7.52	3	NC*
Female	2.58	3	NC*
Total	10.10	6	59

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	3.15	0	NC*
Female	2.55	1	NC*
Total	5.70	1	NC*

**Kidney and Renal Pelvis**

Male	12.34	7	57
Female	8.21	10	122
Total	20.55	17	83

**Larynx**

Male	7.09	6	85
Female	1.90	2	NC*
Total	9.00	8	89

**Leukemia**

Male	9.75	15	154
Female	8.08	10	124
Total	17.82	25	140

**Liver and Intrahepatic Bile Ducts**

Male	4.80	3	NC*
Female	2.14	4	NC*
Total	6.94	7	101

**Lung and Bronchus**

Male	66.44	73	110
Female	56.67	79	139 ~+
Total	123.10	152	123 #+

**Oral Cavity and Pharynx**

Male	13.09	17	130
Female	6.73	6	89
Total	19.82	23	116

**Ovary**

Female	15.80	17	108
--------	-------	----	-----

**Pancreas**

Male	8.73	10	115
Female	9.80	6	61
Total	18.53	16	86

**Prostate**

Male	130.91	141	108
------	--------	-----	-----

**Stomach**

Male	8.70	10	115
Female	5.73	4	NC*
Total	14.43	14	97

**Testis**

Male	4.81	6	125
------	------	---	-----

**Thyroid**

Male	2.80	5	179
Female	7.74	10	129
Total	10.54	15	142

**Uteri, Corpus and Uterus, NOS**

Female	26.33	22	84
--------	-------	----	----

**All Sites / Types**

Male	422.61	450	106
Female	426.30	423	99
Total	848.91	873	103

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Raynham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
------------	------------	------------	------------	------------	------------

**Bladder, Urinary**

Male	6.81	3	NC*
Female	2.49	3	NC*
Total	9.30	6	65

**Brain and Other Central Nervous System**

Male	2.19	4	NC*
Female	1.75	1	NC*
Total	3.93	5	127

**Breast**

Male	0.33	0	NC*
Female	44.92	44	98
Total	45.25	44	97

**Cervix Uteri**

Female	2.52	3	NC*
--------	------	---	-----

**Colon / Rectum**

Male	17.09	28	164 #+
Female	15.51	23	148
Total	32.60	51	156 ~+

**Esophagus**

Male	2.60	0	NC*
Female	0.75	1	NC*
Total	3.36	1	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	1.06	2	NC*
Female	0.81	3	NC*
Total	1.87	5	267

**Kidney and Renal Pelvis**

Male	4.30	4	NC*
Female	2.63	3	NC*
Total	6.93	7	101

**Larynx**

Male	2.49	0	NC*
Female	0.64	1	NC*
Total	3.13	1	NC*

**Leukemia**

Male	3.32	4	NC*
Female	2.54	2	NC*
Total	5.86	6	102

**Liver and Intrahepatic Bile Ducts**

Male	1.66	3	NC*
Female	0.65	0	NC*
Total	2.31	3	NC*

**Lung and Bronchus**

Male	22.43	36	161 #+
Female	18.21	18	99
Total	40.64	54	133

**Melanoma of Skin**

Male	4.80	12	250 ~+
Female	3.65	4	NC*
Total	8.45	16	189 #+

**Multiple Myeloma**

Male	1.38	1	NC*
Female	1.19	2	NC*
Total	2.58	3	NC*

**Non-Hodgkin('s) Lymphoma**

Male	5.71	8	140
Female	5.01	9	180
Total	10.72	17	159

**Oral Cavity and Pharynx**

Male	4.63	5	108
Female	2.16	1	NC*
Total	6.79	6	88

**Ovary**

Female	5.22	6	115
--------	------	---	-----

**Pancreas**

Male	2.94	3	NC*
Female	2.91	2	NC*
Total	5.85	5	86

**Prostate**

Male	44.59	48	108
------	-------	----	-----

**Stomach**

Male	2.90	3	NC*
Female	1.65	0	NC*
Total	4.55	3	NC*

**Testis**

Male	1.56	3	NC*
------	------	---	-----

**Thyroid**

Male	0.97	1	NC*
Female	2.54	1	NC*
Total	3.52	2	NC*

**Uteri, Corpus and Uterus, NOS**

Female	8.85	8	90
--------	------	---	----

**All Sites / Types**

Male	143.17	184	129 ~+
Female	135.80	140	103
Total	278.97	324	116 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Reading

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	15.58	12	77	Male	10.67	22	206 ~+
Female	5.96	7	118	Female	8.19	14	171
Total	21.54	19	88	Total	18.86	36	191 ^+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	4.80	5	104	Male	3.09	2	NC*
Female	3.88	2	NC*	Female	2.74	4	NC*
Total	8.68	7	81	Total	5.83	6	103
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.75	0	NC*	Male	12.80	12	94
Female	99.63	120	120	Female	11.53	14	121
Total	100.38	120	120	Total	24.33	26	107
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	5.56	6	108	Male	10.18	9	88
				Female	4.88	4	NC*
				Total	15.06	13	86
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	38.93	31	80	Female	11.57	15	130
Female	37.20	39	105				
Total	76.13	70	92				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	5.80	8	138	Male	6.66	6	90
Female	1.82	1	NC*	Female	6.92	6	87
Total	7.61	9	118	Total	13.58	12	88
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	2.37	2	NC*	Male	99.80	79	79 #-
Female	1.83	2	NC*				
Total	4.21	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	9.47	4	NC*	Male	6.63	9	136
Female	5.95	6	101	Female	4.01	3	NC*
Total	15.42	10	65	Total	10.65	12	113
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	5.48	1	NC*	Male	3.54	2	NC*
Female	1.40	0	NC*				
Total	6.88	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	7.42	5	67	Male	2.15	4	NC*
Female	5.86	2	NC*	Female	5.62	5	89

Total	13.28	7	53
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	3.69	2	NC*
Female	1.52	0	NC*
Total	5.21	2	NC*
<b><u>Lung and Bronchus</u></b>			
Male	50.29	46	91
Female	40.96	27	66 #-
Total	91.26	73	80

Total	7.77	9	116
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	19.43	26	134
<b><u>All Sites / Types</u></b>			
Male	321.40	279	87 #-
Female	308.31	326	106
Total	629.71	605	96

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rehoboth

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	5.83	7	120
Female	2.01	0	NC*
Total	7.84	7	89
<b><u>Brain and Other Central Nervous System</u></b>			
Male	2.01	0	NC*
Female	1.50	0	NC*
Total	3.51	0	NC*
<b><u>Breast</u></b>			
Male	0.30	0	NC*
Female	38.79	48	124
Total	39.08	48	123
<b><u>Cervix Uteri</u></b>			
Female	2.27	2	NC*
<b><u>Colon / Rectum</u></b>			
Male	14.72	5	34 ~-
Female	12.52	9	72
Total	27.24	14	51 ~-
<b><u>Esophagus</u></b>			
Male	2.37	2	NC*
Female	0.61	0	NC*
Total	2.98	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.97	3	NC*
Female	0.73	1	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	4.38	3	NC*
Female	3.20	2	NC*
Total	7.59	5	66
<b><u>Multiple Myeloma</u></b>			
Male	1.23	0	NC*
Female	0.98	2	NC*
Total	2.20	2	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	5.13	3	NC*
Female	4.15	4	NC*
Total	9.28	7	75
<b><u>Oral Cavity and Pharynx</u></b>			
Male	4.35	3	NC*
Female	1.83	0	NC*
Total	6.18	3	NC*
<b><u>Ovary</u></b>			
Female	4.52	5	111
<b><u>Pancreas</u></b>			
Male	2.60	1	NC*
Female	2.34	0	NC*
Total	4.94	1	NC*
<b><u>Prostate</u></b>			
Male	39.47	30	76

Total	1.70	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.92	3	NC*	Male	2.55	1	NC*
Female	2.20	1	NC*	Female	1.35	2	NC*
Total	6.12	4	NC*	Total	3.90	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.30	1	NC*	Male	1.40	1	NC*
Female	0.54	0	NC*				
Total	2.83	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.94	2	NC*	Male	0.92	1	NC*
Female	2.16	4	NC*	Female	2.32	1	NC*
Total	5.11	6	118	Total	3.24	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.52	2	NC*				
Female	0.53	0	NC*	Female	7.56	7	93
Total	2.04	2	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	19.62	12	61	Male	126.73	82	65 ^-
Female	14.87	13	87	Female	114.65	109	95
Total	34.49	25	72	Total	241.39	191	79 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Revere

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	30.69	36	117	Male	19.01	17	89
Female	11.98	12	100	Female	14.67	12	82
Total	42.67	48	112	Total	33.68	29	86
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	8.29	14	169	Male	5.76	11	191
Female	7.00	5	71	Female	5.23	3	NC*
Total	15.29	19	124	Total	10.99	14	127
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.38	3	NC*	Male	23.41	28	120
Female	174.87	204	117 #+	Female	22.04	31	141
Total	176.25	207	117 #+	Total	45.45	59	130
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
				Male	17.13	21	123
Female	9.68	12	124	Female	8.91	9	101

				Total	26.04	30	115
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	75.32	95	126 #+				
Female	75.56	84	111	Female	20.37	26	128
Total	150.88	179	119 #+				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	10.18	10	98	Male	12.41	10	81
Female	3.68	4	NC*	Female	13.81	27	196 ~+
Total	13.86	14	101	Total	26.22	37	141
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	4.20	9	214	Male	177.94	173	97
Female	3.38	7	207				
Total	7.58	16	211 #+				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	16.69	19	114	Male	12.70	23	181 #+
Female	10.92	18	165	Female	8.20	12	146
Total	27.61	37	134	Total	20.90	35	167 ~+
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	9.32	17	182 #+	Male	6.42	8	125
Female	2.43	7	288 #+				
Total	11.75	24	204 ~+				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	13.86	7	51	Male	3.58	6	168
Female	11.03	19	172 #+	Female	9.79	5	51
Total	24.88	26	104	Total	13.37	11	82
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	6.46	11	170				
Female	2.98	2	NC*	Female	33.62	41	122
Total	9.44	13	138				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	92.78	134	144 ^+	Male	588.35	697	118 ^+
Female	75.78	112	148 ^+	Female	568.96	706	124 ^+
Total	168.56	246	146 ^+	Total	1157.30	1403	121 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Richmond

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.59	0	NC*	Male	1.03	1	NC*
Female	0.51	2	NC*	Female	0.70	0	NC*

Total	2.09	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>			
Male	0.44	0	NC*
Female	0.33	0	NC*
Total	0.77	0	NC*
<b><u>Breast</u></b>			
Male	0.08	0	NC*
Female	8.96	9	100
Total	9.03	9	100
<b><u>Cervix Uteri</u></b>			
Female	0.47	0	NC*
<b><u>Colon / Rectum</u></b>			
Male	3.93	2	NC*
Female	3.16	2	NC*
Total	7.09	4	NC*
<b><u>Esophagus</u></b>			
Male	0.58	1	NC*
Female	0.15	0	NC*
Total	0.74	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.18	0	NC*
Female	0.14	1	NC*
Total	0.33	1	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	0.94	0	NC*
Female	0.53	0	NC*
Total	1.46	0	NC*
<b><u>Larynx</u></b>			
Male	0.55	0	NC*
Female	0.13	0	NC*
Total	0.68	0	NC*
<b><u>Leukemia</u></b>			
Male	0.71	0	NC*
Female	0.49	0	NC*
Total	1.20	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	0.36	0	NC*
Female	0.13	1	NC*
Total	0.49	1	NC*
<b><u>Lung and Bronchus</u></b>			
Male	5.05	1	NC*
Female	3.67	0	NC*
Total	8.72	1	NC*

Total	1.73	1	NC*
<b><u>Multiple Myeloma</u></b>			
Male	0.31	0	NC*
Female	0.24	0	NC*
Total	0.56	0	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.22	1	NC*
Female	0.99	2	NC*
Total	2.21	3	NC*
<b><u>Oral Cavity and Pharynx</u></b>			
Male	1.01	3	NC*
Female	0.43	0	NC*
Total	1.44	3	NC*
<b><u>Ovary</u></b>			
Female	1.03	1	NC*
<b><u>Pancreas</u></b>			
Male	0.67	0	NC*
Female	0.59	0	NC*
Total	1.26	0	NC*
<b><u>Prostate</u></b>			
Male	10.00	5	50
<b><u>Stomach</u></b>			
Male	0.67	0	NC*
Female	0.33	0	NC*
Total	1.00	0	NC*
<b><u>Testis</u></b>			
Male	0.24	0	NC*
<b><u>Thyroid</u></b>			
Male	0.19	0	NC*
Female	0.46	0	NC*
Total	0.65	0	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	1.78	0	NC*
<b><u>All Sites / Types</u></b>			
Male	31.80	14	44 ^-
Female	27.07	18	66
Total	58.87	32	54 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rochester

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.76	5	181	Male	2.02	3	NC*
Female	0.87	2	NC*	Female	1.42	1	NC*
Total	3.63	7	193	Total	3.44	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.91	2	NC*	Male	0.57	0	NC*
Female	0.66	2	NC*	Female	0.43	0	NC*
Total	1.57	4	NC*	Total	1.00	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.14	0	NC*	Male	2.39	2	NC*
Female	17.15	12	70	Female	1.80	1	NC*
Total	17.28	12	69	Total	4.19	3	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.01	1	NC*	Male	2.01	0	NC*
				Female	0.80	1	NC*
				Total	2.81	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	6.91	2	NC*	Female	1.99	5	251
Female	5.41	6	111				
Total	12.31	8	65				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.10	0	NC*	Male	1.22	0	NC*
Female	0.26	0	NC*	Female	1.00	0	NC*
Total	1.36	0	NC*	Total	2.22	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.43	0	NC*	Male	17.88	12	67
Female	0.32	0	NC*				
Total	0.75	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.81	1	NC*	Male	1.22	0	NC*
Female	0.96	0	NC*	Female	0.58	1	NC*
Total	2.76	1	NC*	Total	1.80	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.05	2	NC*	Male	0.61	0	NC*
Female	0.23	0	NC*				
Total	1.28	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.37	1	NC*	Male	0.42	1	NC*
Female	0.95	0	NC*	Female	1.04	1	NC*
Total	2.32	1	NC*	Total	1.45	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.70	0	NC*				

Female	0.23	0	NC*	Female	3.33	2	NC*
Total	0.92	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	8.96	9	100	Male	58.32	43	74 #–
Female	6.39	5	78	Female	50.19	47	94
Total	15.35	14	91	Total	108.50	90	83

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

– indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rockland

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	9.47	14	148	Male	6.64	18	271 ^+
Female	3.87	3	NC*	Female	5.40	11	204 #+
Total	13.34	17	127	Total	12.03	29	241 ^+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	3.11	2	NC*	Male	1.87	1	NC*
Female	2.60	3	NC*	Female	1.76	2	NC*
Total	5.72	5	87	Total	3.63	3	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.46	0	NC*	Male	8.02	4	NC*
Female	63.63	69	108	Female	7.57	6	79
Total	64.09	69	108	Total	15.59	10	64
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	3.74	1	NC*	Male	6.16	5	81
				Female	3.14	3	NC*
				Total	9.30	8	86
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	23.73	27	114	Female	7.48	8	107
Female	24.25	24	99				
Total	47.98	51	106				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	3.49	5	143	Male	4.03	6	149
Female	1.18	0	NC*	Female	4.50	5	111
Total	4.67	5	107	Total	8.53	11	129
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.65	2	NC*	Male	60.75	66	109
Female	1.32	0	NC*				
Total	2.97	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	5.80	5	86	Male	4.00	6	150

Female	3.84	3	NC*
Total	9.64	8	83
<b><u>Larynx</u></b>			
Male	3.31	8	241 #+
Female	0.89	2	NC*
Total	4.20	10	238 #+

<b><u>Leukemia</u></b>			
Male	4.71	3	NC*
Female	3.88	6	155
Total	8.59	9	105

<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	2.26	2	NC*
Female	0.99	1	NC*
Total	3.25	3	NC*

<b><u>Lung and Bronchus</u></b>			
Male	30.79	46	149 #+
Female	26.36	50	190 ^+
Total	57.15	96	168 ^+

Female	2.63	0	NC*
Total	6.63	6	91

<b><u>Testis</u></b>			
Male	2.61	1	NC*

<b><u>Thyroid</u></b>			
Male	1.40	2	NC*
Female	3.86	6	155
Total	5.26	8	152

<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	12.26	8	65

<b><u>All Sites / Types</u></b>			
Male	197.56	233	118 #+
Female	199.43	222	111
Total	396.99	455	115 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rockport

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>			
Male	7.03	4	NC*
Female	3.06	4	NC*
Total	10.09	8	79

<b><u>Brain and Other Central Nervous System</u></b>			
Male	1.76	0	NC*
Female	1.59	1	NC*
Total	3.35	1	NC*

<b><u>Breast</u></b>			
Male	0.32	3	NC*
Female	42.91	39	91
Total	43.23	42	97

<b><u>Cervix Uteri</u></b>			
Female	2.16	1	NC*

<b><u>Colon / Rectum</u></b>			
Male	17.19	12	70

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Melanoma of Skin</u></b>			
Male	4.27	3	NC*
Female	3.46	5	144
Total	7.74	8	103

<b><u>Multiple Myeloma</u></b>			
Male	1.33	0	NC*
Female	1.31	0	NC*
Total	2.65	0	NC*

<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	5.19	2	NC*
Female	5.36	7	131
Total	10.55	9	85

<b><u>Oral Cavity and Pharynx</u></b>			
Male	4.05	3	NC*
Female	2.22	2	NC*
Total	6.26	5	80

<b><u>Ovary</u></b>			
---------------------	--	--	--

Female	19.25	12	62	Female	4.90	4	NC*
Total	36.44	24	66 #-				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.40	2	NC*	Male	2.88	2	NC*
Female	0.94	0	NC*	Female	3.50	2	NC*
Total	3.34	2	NC*	Total	6.39	4	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.77	1	NC*	Male	41.07	27	66 #-
Female	0.69	0	NC*				
Total	1.46	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.85	3	NC*	Male	2.95	1	NC*
Female	2.68	2	NC*	Female	2.11	6	284 #+
Total	6.53	5	77	Total	5.06	7	138
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.20	1	NC*	Male	1.03	0	NC*
Female	0.60	1	NC*				
Total	2.79	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.02	6	198	Male	0.75	1	NC*
Female	2.69	5	186	Female	2.09	2	NC*
Total	5.71	11	192	Total	2.84	3	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.49	0	NC*	Female	8.32	14	168
Female	0.75	1	NC*				
Total	2.24	1	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	21.16	10	47 #-	Male	133.76	88	66 ^-
Female	18.55	13	70	Female	139.98	134	96
Total	39.71	23	58 ~-	Total	273.74	222	81 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rowe

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.40	0	NC*	Male	0.24	0	NC*
Female	0.12	0	NC*	Female	0.15	1	NC*
Total	0.52	0	NC*	Total	0.38	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.09	0	NC*	Male	0.07	0	NC*

Female	0.07	0	NC*
Total	0.16	0	NC*
<b>Breast</b>			
Male	0.02	0	NC*
Female	1.95	2	NC*
Total	1.96	2	NC*
<b>Cervix Uteri</b>			
Female	0.09	0	NC*
<b>Colon / Rectum</b>			
Male	0.96	0	NC*
Female	0.73	0	NC*
Total	1.70	0	NC*
<b>Esophagus</b>			
Male	0.14	0	NC*
Female	0.04	0	NC*
Total	0.17	0	NC*
<b>Hodgkin's Disease (Hodgkin Lymphoma)</b>			
Male	0.04	0	NC*
Female	0.03	0	NC*
Total	0.06	0	NC*
<b>Kidney and Renal Pelvis</b>			
Male	0.21	0	NC*
Female	0.12	0	NC*
Total	0.33	0	NC*
<b>Larynx</b>			
Male	0.12	0	NC*
Female	0.03	0	NC*
Total	0.15	0	NC*
<b>Leukemia</b>			
Male	0.16	0	NC*
Female	0.11	0	NC*
Total	0.28	0	NC*
<b>Liver and Intrahepatic Bile Ducts</b>			
Male	0.08	0	NC*
Female	0.03	0	NC*
Total	0.11	0	NC*
<b>Lung and Bronchus</b>			
Male	1.16	1	NC*
Female	0.83	0	NC*
Total	1.99	1	NC*

Female	0.05	1	NC*
Total	0.13	1	NC*
<b>Non-Hodgkin('s) Lymphoma</b>			
Male	0.29	0	NC*
Female	0.22	0	NC*
Total	0.51	0	NC*
<b>Oral Cavity and Pharynx</b>			
Male	0.23	0	NC*
Female	0.10	0	NC*
Total	0.33	0	NC*
<b>Ovary</b>			
Female	0.22	0	NC*
<b>Pancreas</b>			
Male	0.16	0	NC*
Female	0.14	1	NC*
Total	0.30	1	NC*
<b>Prostate</b>			
Male	2.27	1	NC*
<b>Stomach</b>			
Male	0.17	0	NC*
Female	0.08	0	NC*
Total	0.25	0	NC*
<b>Testis</b>			
Male	0.04	0	NC*
<b>Thyroid</b>			
Male	0.04	0	NC*
Female	0.09	0	NC*
Total	0.13	0	NC*
<b>Uteri, Corpus and Uterus, NOS</b>			
Female	0.39	0	NC*
<b>All Sites / Types</b>			
Male	7.40	2	NC*
Female	6.00	5	83
Total	13.41	7	52

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rowley

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.64	0	NC*	Male	1.98	3	NC*
Female	0.88	0	NC*	Female	1.48	2	NC*
Total	3.52	0	NC*	Total	3.46	5	144
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.93	1	NC*	Male	0.54	0	NC*
Female	0.70	0	NC*	Female	0.42	0	NC*
Total	1.63	1	NC*	Total	0.96	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.13	0	NC*	Male	2.36	3	NC*
Female	17.04	13	76	Female	1.85	2	NC*
Total	17.17	13	76	Total	4.22	5	119
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.08	1	NC*	Male	1.90	1	NC*
				Female	0.80	0	NC*
				Total	2.70	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	6.62	5	76	Female	2.02	4	NC*
Female	5.52	10	181				
Total	12.14	15	124				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.03	1	NC*	Male	1.16	0	NC*
Female	0.27	0	NC*	Female	1.01	0	NC*
Total	1.30	1	NC*	Total	2.17	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.49	0	NC*	Male	16.89	17	101
Female	0.38	0	NC*				
Total	0.87	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.72	0	NC*	Male	1.16	1	NC*
Female	0.96	0	NC*	Female	0.60	1	NC*
Total	2.68	0	NC*	Total	1.76	2	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.98	0	NC*	Male	0.75	4	NC*
Female	0.23	0	NC*				
Total	1.21	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.37	3	NC*	Male	0.43	0	NC*
Female	1.00	3	NC*	Female	1.15	1	NC*
Total	2.37	6	254	Total	1.58	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.66	0	NC*	Female	3.24	1	NC*
Female	0.23	0	NC*				
Total	0.89	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	8.53	11	129	Male	56.09	55	98

Female	6.31	5	79	Female	50.64	46	91
Total	14.84	16	108	Total	106.73	101	95

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Royalston

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.81	1	NC*	Male	0.55	0	NC*
Female	0.25	0	NC*	Female	0.35	1	NC*
Total	1.06	1	NC*	Total	0.90	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.24	0	NC*	Male	0.16	0	NC*
Female	0.17	0	NC*	Female	0.12	0	NC*
Total	0.41	0	NC*	Total	0.28	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.04	0	NC*	Male	0.65	0	NC*
Female	4.21	3	NC*	Female	0.49	1	NC*
Total	4.25	3	NC*	Total	1.14	1	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.24	0	NC*	Male	0.53	0	NC*
				Female	0.21	0	NC*
				Total	0.73	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	2.00	5	250	Female	0.49	1	NC*
Female	1.59	0	NC*				
Total	3.58	5	140				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.30	0	NC*	Male	0.34	1	NC*
Female	0.08	0	NC*	Female	0.29	0	NC*
Total	0.37	0	NC*	Total	0.63	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.11	0	NC*	Male	5.01	1	NC*
Female	0.08	0	NC*				
Total	0.20	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.49	0	NC*	Male	0.34	0	NC*
Female	0.25	1	NC*	Female	0.17	0	NC*
Total	0.74	1	NC*	Total	0.51	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.28	0	NC*	Male	0.16	0	NC*

Female	0.06	0	NC*
Total	0.34	0	NC*

#### Leukemia

Male	0.38	0	NC*
Female	0.25	0	NC*
Total	0.63	0	NC*

#### Liver and Intrahepatic Bile Ducts

Male	0.19	0	NC*
Female	0.06	0	NC*
Total	0.25	0	NC*

#### Lung and Bronchus

Male	2.55	0	NC*
Female	1.70	0	NC*
Total	4.25	0	NC*

#### Thyroid

Male	0.11	0	NC*
Female	0.25	0	NC*
Total	0.35	0	NC*

#### Uteri, Corpus and Uterus, NOS

Female	0.81	1	NC*
--------	------	---	-----

#### All Sites / Types

Male	16.31	8	49 #-
Female	13.07	8	61
Total	29.38	16	54 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Russell**

### **Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<u>Bladder, Urinary</u>			
Male	1.07	0	NC*
Female	0.34	0	NC*
Total	1.41	0	NC*

<u>Brain and Other Central Nervous System</u>			
Male	0.33	0	NC*
Female	0.25	2	NC*
Total	0.58	2	NC*

<u>Breast</u>			
Male	0.05	0	NC*
Female	6.21	3	NC*
Total	6.26	3	NC*

<u>Cervix Uteri</u>			
Female	0.38	0	NC*

<u>Colon / Rectum</u>			
Male	2.67	4	NC*
Female	2.11	0	NC*
Total	4.79	4	NC*

<u>Esophagus</u>			
Male	0.40	0	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<u>Melanoma of Skin</u>			
Male	0.75	0	NC*
Female	0.53	0	NC*
Total	1.28	0	NC*

<u>Multiple Myeloma</u>			
Male	0.21	0	NC*
Female	0.16	0	NC*
Total	0.37	0	NC*

<u>Non-Hodgkin(s) Lymphoma</u>			
Male	0.89	0	NC*
Female	0.69	1	NC*
Total	1.58	1	NC*

<u>Oral Cavity and Pharynx</u>			
Male	0.71	0	NC*
Female	0.30	0	NC*
Total	1.01	0	NC*

<u>Ovary</u>			
Female	0.73	0	NC*

<u>Pancreas</u>			
Male	0.46	1	NC*

Female	0.10	0	NC*	Female	0.39	1	NC*
Total	0.50	0	NC*	Total	0.85	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.17	0	NC*	Male	6.71	8	119
Female	0.13	0	NC*				
Total	0.30	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.66	0	NC*	Male	0.46	0	NC*
Female	0.36	3	NC*	Female	0.23	0	NC*
Total	1.01	3	NC*	Total	0.69	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.38	1	NC*	Male	0.25	0	NC*
Female	0.08	0	NC*				
Total	0.46	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.52	0	NC*	Male	0.15	0	NC*
Female	0.37	0	NC*	Female	0.39	0	NC*
Total	0.88	0	NC*	Total	0.54	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.25	0	NC*				
Female	0.09	0	NC*	Female	1.19	2	NC*
Total	0.34	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	3.41	4	NC*	Male	22.00	20	91
Female	2.39	5	210	Female	18.71	18	96
Total	5.80	9	155	Total	40.71	38	93

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels